View in EDS HTML Full Text PDF Full Text

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.

Saved in:
Bibliographic Details
Title: NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Authors: Lee, Eudocia Q.1 (AUTHOR) eqlee@partners.org, Zhang, Peixin2 (AUTHOR), Wen, Patrick Y.1 (AUTHOR), Gerstner, Elizabeth R.3 (AUTHOR), Reardon, David A.1 (AUTHOR), Aldape, Kenneth D.4 (AUTHOR), deGroot, John F.5 (AUTHOR), Pan, Edward6 (AUTHOR), Raizer, Jeffrey J.7 (AUTHOR), Kim, Lyndon J.8 (AUTHOR), Chmura, Steven J.9 (AUTHOR), Robins, H. Ian10 (AUTHOR), Connelly, Jennifer M.11 (AUTHOR), Battiste, James D.12 (AUTHOR), Villano, John L.13 (AUTHOR), Wagle, Naveed14 (AUTHOR), Merrell, Ryan T.15 (AUTHOR), Wendland, Merideth M.16 (AUTHOR), Mehta, Minesh P.17 (AUTHOR)
Source: Cancer (0008543X). Jun2020, Vol. 126 Issue 12, p2821-2828. 8p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:0008543X
DOI:10.1002/cncr.32811